1Braunwald E,Antman EM,Beasley JW,et al.ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article:a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina).J Am Coll Cardiol,2002,40:1366-1374.
2Monagle P,Chan A,Massicotte P,et al.Antithrombotic therapy in children:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest,2004,126(Suppl 3):645S-687S.
3Mousa SA.Antiplatelet therapies:from aspirin to GP Ⅱb/Ⅲa-receptor antagonists and beyond.Drug Discov Today,1999,4:522 -561.
6Lapchak PA, Araujo DM. Therapeutic Potential of Platelet Glycoprotein Ⅱb/Ⅲa Receptor Antagonists in the Management of Ischemic Stroke. Am J Cardiovasc Drugs, 2003, 3:87 -94.
7Seitz R J,Hanzavi M,Junghans U,et al.Thrombolysis with recombinant tissue plasminogen actiwtor and tirofiban in stroke:preliminary obserrations.Stroke,2003,34:1932-1935.
8Seitz RJ,Meisel S,Moll M,et al.Partial rescue of the perfusion deficit area by thrombolysis.J Magn Reson Imaging,2005,22:199-205.
9Straub S,Junghans U,Jovaaovic V,et al.Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion.Stroke,2004,35:705 -709.
10Mangiafico S,Cellerini M,Nencini P,et al.Intravenous glycoprotein Ⅱ b/Ⅲa inhibitor (tirofiban) followed by intra-arterial urokinase and mechaaical thrombolysis in stroke.AJNR Am J Neuroradiol,2005,26:2595-2601.
